Award
National Heart, Lung, and Blood Institute 5R44HL174221-03
UroMarker Test Panel for Obstructive Sleep Apnea
Recipient
PGXL TECHNOLOGIES, LLC
Award Amount
$957,571.00
Ceiling
$957,571.00
Awarded
August 05, 2026
Identifier
5R44HL174221-03
Award to PGXL TECHNOLOGIES, LLC for developing a urine-based test panel to screen and diagnose pediatric Obstructive Sleep Apnea, with a focus on validating biomarkers and supporting FDA clearance.
Description
PGXL Technologies is developing a non-invasive, urine-based multiplexed immunoassay for screening children for Obstructive Sleep Apnea (OSA). The project aims to validate four biomarkers (urocortin-3, kallikrein-1, orosomucoid-1, and uromodulin) in urine samples to improve diagnosis, monitoring, and screening of OSA in pediatric populations.